See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: May 1, 2006

McCune-Albright Syndrome Ulcerative Colitis Diabetic Foot Ulcers

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

McCune-Albright Syndrome

This study will evaluate the safety and effectiveness of a drug called Faslodex (fulvestrant) to treat early puberty in girls with McCune-Albright Syndrome (MAS). Females younger than 11 diagnosed with progressive precocious puberty before age 8 who have not received any prior treatment for early puberty may qualify.

Research sites are located throughout the United States.

More information

Please see


Ulcerative Colitis

The RESTORE study is being conducted in the United States and Europe to evaluate the safety and effectiveness of the drug visilizumab to treat severe ulcerative colitis. Volunteers at least 18 who have an active disease despite ongoing treatment with steroids may qualify. Eligible patients will participate in 90 days of intensive weekly-to-monthly evaluations and every third month follow-up for one year.

Research sites are located across the United States.

More information

Please see


Diabetic Foot Ulcers

HOPE Research Institute is enrolling diabetic adults in a research study of an investigational treatment for diabetic foot wounds. Candidates 18-80 who have diabetes and at least one foot wound may be eligible. Study participants will receive study supervision by a board-certified podiatrist, study-related tests and exams, study medication, as well as compensation for time and travel.

The research site is in Phoenix, Ariz.

More information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.